Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
Johnson Controls(JCI) - Get Report : When a company has a transformation catalyst on the horizon, investors should take notice, Cramer told viewers. That's why the stock of Johnson Controls, which has not one, but two huge catalysts coming, is worth noting.
Cramer has proposed for years Johnson Controls break itself up to unlock value. Indeed, the company announced just that, the spinoff of its slower-growing automotive seating division later this year. That leaves Johnson Controls as an industrial, with building efficiency and power solutions businesses.
But Johnson Controls took things one step further, announcing the acquisition of Tyco International (TYC) for $16.5 billion earlier this year. Cramer said this move makes the company a true diversified industrial that can bundle a host of construction products, all while enjoying $500 million in synergies over the next three years.
Given these two catalysts are both coming this year, Cramer said Johnson Controls will demand a higher valuation than its current 10.5 times earnings. The stock will be compared to other diversified industrials including Honeywell(HON) - Get Report at 16 times earnings and General Electric(GE) - Get Report at 18 times earnings.
DexCom(DXCM) - Get Report : In his "Executive Decision" segment, Cramer sat down with Kevin Sayer, president and CEO of glucose monitoring company DexCom. Shares of DexCom are up 39% since Cramer last checked in five months ago and a full 700% over the past five years.
Sayer said not all glucose devices are created equal and DexCom has the first device being considered to make insulin dosing decisions on its own. He said using a DexCom device is far superior to pricking a finger to do it manually. The DexCom app allows patients to see arrows and trends and can even send alerts to family and medical providers when needed.
DexCom patients are also always less than 90 days away from the latest technology, as they can upgrade when the under-the-skin sensor needs replacing. The DexCom app is also regularly updated with new features for patients and their doctors.
Sayer noted DexCom has made history with its device and will do the same when it comes to commercializing it,. The company is pushing forward with new channels and partners to get the technology in front of more patients.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.
At the time of publication, Cramer's Action Alerts PLUS had a position in GE.